The decision, approved by the Governing Council at the proposal of the Department of Health, will allow for the extension of current framework procurement agreements for the next 24 months. This action ensures the continuous supply of high-impact clinical drugs needed to address conditions such as lymphomas, leukemia, breast and stomach tumors, as well as various immune-mediated diseases.

Of the total budget, 99.9 million euros are earmarked for the acquisition of exclusive drugs, those protected by patents without generic or biosimilar alternatives. The remaining 22.7 million will be used to purchase key active ingredients such as adalimumab, rituximab, and trastuzumab.

These treatments are vital in daily hospital practice. While adalimumab is used in chronic inflammatory processes such as rheumatoid arthritis or Crohn's disease, rituximab is key in addressing hematological cancers and autoimmune conditions. Meanwhile, trastuzumab is specifically used for breast and gastric tumors.

The Department of Health explained that the adjustment in funding responds to fluctuations in unit prices, the integration of new therapeutic references, and market changes following the loss of exclusivity for some products. With this investment, the regional executive strengthens the capacity of the Canary Health Service to provide advanced therapies to patients with serious and long-term illnesses.